These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34591420)

  • 1. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
    Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
    Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
    Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y
    BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study.
    Fukuda K; Osumi H; Yoshinami Y; Ooki A; Takashima A; Wakatsuki T; Hirano H; Nakayama I; Ouchi K; Sawada R; Fukuoka S; Ogura M; Takahari D; Chin K; Shoji H; Okita N; Kato K; Ishizuka N; Boku N; Yamaguchi K; Shinozaki E
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):369. PubMed ID: 39066951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
    Montagut C; Argilés G; Ciardiello F; Poulsen TT; Dienstmann R; Kragh M; Kopetz S; Lindsted T; Ding C; Vidal J; Clausell-Tormos J; Siravegna G; Sánchez-Martín FJ; Koefoed K; Pedersen MW; Grandal MM; Dvorkin M; Wyrwicz L; Rovira A; Cubillo A; Salazar R; Desseigne F; Nadal C; Albanell J; Zagonel V; Siena S; Fumi G; Rospo G; Nadler P; Horak ID; Bardelli A; Tabernero J
    JAMA Oncol; 2018 Apr; 4(4):e175245. PubMed ID: 29423521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
    van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
    Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.
    Nicolazzo C; Barault L; Caponnetto S; De Renzi G; Belardinilli F; Bottillo I; Bargiacchi S; Macagno M; Grammatico P; Giannini G; Cortesi E; Di Nicolantonio F; Gazzaniga P
    Cancer Lett; 2021 Jun; 507():89-96. PubMed ID: 33744389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
    Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
    Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
    Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
    Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
    Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.
    D'Onofrio R; Caputo F; Prampolini F; Spallanzani A; Gelsomino F; Bettelli S; Manfredini S; Reggiani Bonetti L; Carotenuto P; Bocconi A; Dominici M; Luppi G; Salati M
    Tumori; 2023 Aug; 109(4):387-393. PubMed ID: 36113407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
    Rossini D; Germani MM; Pagani F; Pellino A; Dell'Aquila E; Bensi M; Liscia N; Moretto R; Boccaccino A; Prisciandaro M; Manglaviti S; Schirripa M; Vivolo R; Scartozzi M; Santini D; Salvatore L; Pietrantonio F; Loupakis F; Falcone A; Cremolini C
    Clin Colorectal Cancer; 2020 Sep; 19(3):191-199.e6. PubMed ID: 32466976
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sunakawa Y; Nakamura M; Ishizaki M; Kataoka M; Satake H; Kitazono M; Yanagisawa H; Kawamoto Y; Kuramochi H; Ohori H; Nakamura M; Maeda F; Komeno C; Sonezaki T; Takeuchi M; Fujii M; Yoshino T; Tsuji A; Ichikawa W
    JCO Precis Oncol; 2020 Nov; 4():898-911. PubMed ID: 35050760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
    Thomsen CB; Andersen RF; Lindebjerg J; Hansen TF; Jensen LH; Jakobsen A
    Clin Colorectal Cancer; 2019 Mar; 18(1):28-33.e3. PubMed ID: 30459076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
    Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
    Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.